Systemic :
Topical OTC and Prescription
This is one of the few reports of this type on the market that attempts an analyses of both the systemic and topical markets.
Further the systemic market is subdivided into analyses that includes :
Azoles
Polyenes
Pyrimidines
Allylamines
Echinodians
According to Dr Scraggs the total market will see a growth rate decline with an average growth rate (AAGR) from 2002-2009 of only 39.1 per cent, revenues by 2009 will be approaching $8 billion. Systemic antifungals, not surprisingly dominate this market with a 60 per cent market share. This is a market you must become successful in. There is a significant unmet need in this market because the present portfolio of treatments interact unfavourably with other medications, have resistance problems, low spectrum of activity, are fungistatic as opposed to fungicidal and are often toxic. The company that can arrive at a new class of drug that can overcome all these limitations will be guaranteed high profits.
Key Questions Answered in this Report :
Total revenues and growth rates for each market segment from 2002-2009
A list of the important drivers and restraints
Incisive market predictions for each segment and individual drug type
A market share analysis of each segment
New products and new developments
A review of the latest innovations in antifungal vaccine discovery
Analysis of market trends
For more information, kindly visit :
http://www.bharatbook.com/
____________________________________________
